Clinical Trial

A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.
Protocol Amendment History 3 changes
notable Enrollment reduced: 24 -> 18 participants 2026-07-02
notable Primary completion moved earlier: 2029-12-31 -> 2027-12-31 2026-07-02
minor Completion moved earlier: 2043-12-31 -> 2028-12-31 2026-07-02
Trial Details
NCT Number NCT07667868
Lead Sponsor BrightPath Biotherapeutics Co., Ltd.
Conditions Relapsed/Refractory Multiple Myeloma (RRMM)
Enrollment 18 participants
Start Date 2026-10-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10